LY-4101174 is under clinical development by Eli Lilly and Co and currently in Phase I for Cervical Cancer. According to GlobalData, Phase I drugs for Cervical Cancer have an 80% phase transition ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback